EDRN Lung & Aerodigestive Cancers Collaborative Group Meeting

Tuesday, September 24, 2024 (2:30 p.m. to 5:45 p.m.)

Room: Truhlsen Event Center, Room 1001 A

Co-Chair: Marc Lenburg, PhD, Boston University

Co-Chair: Eric Grogan, MD, Vanderbilt University Medical Center

Co-Chair: Laura Rozek, MA, MS, PhD, Georgetown University School of Medicine

DMCC Statistician: Chad He, PhD, Fred Hutchinson Cancer Center

DMCC Staff: Jackie Dahlgren, Fred Hutchinson Cancer Center

NCI Program Directors: Guillermo Marquez, PhD, Wendy Wang, PhD, Zhong Chen, PhD (NIDCR)

Agenda (DRAFT)

Central Daylight Time Agenda Item

2:30 p.m.

Welcome

Guillermo Marquez, PhD; National Cancer Institute

2:30 p.m. – 4:00 p.m.

EDRN Set-Aside Projects

2:30 p.m. – 2:40 p.m.
  • Moffitt CVC

01: Ghulam Rasool, PhD

2:40 p.m. – 2:50 p.m.
  • MD Anderson CVC

02: Sam Hanash, MD PhD

2:50 p.m. – 3:00 p.m.
  • Vanderbilt CVC

03: Eric Grogan, MD

3:00 p.m. – 3:10 p.m.
  • Johns Hopkins CVC

04: David Sidransky, MD

3:10 p.m. – 3:20 p.m.
  • Arizona State University CVC

05: Karen Anderson, MD PhD

3:20 p.m. – 3:30 p.m.
  • Arizona State University BCC

06: Karen Anderson, MD PhD

3:30 p.m. – 3:40 p.m.
  • Boston-UCLA BCC

07: Marc Lenburg, PhD

3:40 p.m. – 3:50 p.m.
  • New York University BCC

08: James Tsay, MD

3:50 p.m. – 4:00 p.m.
  • Pittsburgh, BCC

09: TBD

4:00 p.m. – 4:45 p.m.

Discussion on the Collaborative Project proposals (15 minutes each):

  • Clinical data and biospecimen harmonization
  • Imaging harmonization
  • Biomarker harmonization

4:45 p.m. – 5:15 p.m.

Round-table discussions of Collaborative Project proposals. Open discussion on new perspectives and focus areas that can be coordinated across the group including BCCs, CVCs, and AHEAD

How might the proposed collaborative projects lead to trans-collaborative group publications?

  1. How could the proposed collaborative projects be expanded to include other groups within the EDRN?
  2. Reference sets:
    1. What comprises a good reference set
    2. Discuss cross-center collaborations that will facilitate validation of these approaches and biomarkers -considering available and developing data from CVCs, references sets.
  3. What specific approaches and biomarkers appear most promising?
  4. Which approaches and biomarkers are ready to be moved to validation?

5:15 p.m. – 5:35 p.m.

Report and Synthesis of Round-table Discussions

5:35 p.m. – 5:45 p.m.

Collaborative Group Business

5:45 p.m.

Adjourn